Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Medical Technology Advancements Spur New Opportunity For Investment
http://www.baystreet.ca/articles/yahoonews.aspx?id=1043
Big demand in US for companies like $IME $IMEXF look at $CHEK Check-Cap is a clinical-stage medical diagnostics company developing C-Scan®, the first capsule-based system for preparation-free, colorectal cancer screening.
New Highs coming this week ! https://www.imaginmedicalstock.com/
Ahh you shorts better cover lol !!! #GIVEUP
We know all about it and the big bullets are coming!!
Shorts on the $BKPPF US side seems to be 40-50% of every days volume. #short-squeeze
CFO and CEO insider buy yesterday...
CEO going for buyout with his 7+ million shares, never sold 1
Yep CFO also bought 42k yesterday, CEO going for the buyout ! pic.twitter.com/W79NUKSqET
— CapitalGains (@CUUVETTE350) April 20, 2018
$150 US market cap will happen...
A company like IME with current fundamentals in the U.S , we're looking at minimum $150 million US... and its going to happen fast. Current market cap is tiny, 5 bagger min very safe investment markets won't affect, easy just hold.
US brokers don't even know about us yet..but they will. Company is working on that. IME already has DTC just needs OTCQB so that brokers in the US can recommend, now they can't.
1 positive NR regarding human test results and BOOM ! IME will instantly become a buyout spec play. Best position to be in early because investrors drive the price up.
And IME could come out with many new toys...they have many dif. patents.
$IMEXF 100x More Accurate at Visualizing Tumors
https://financialstrend.com/the-next-big-thing-in-cancer-detection-45758.html
Imagin Medical Closes Oversubscribed Private Placement
https://www.nasdaq.com/press-release/imagin-medical-closes-oversubscribed-private-placement-20180419-00662
"The success of this private placement strengthens Imagin's financial position and our ability to drive the i/Blue technology to the marketplace," said Jim Hutchens, Imagin President and CEO. "We appreciate our investors' confidence."
$BKPPF Have Blockchain Tech Investors Found the Holy Grail?
https://www.entrepreneur.com/article/312127
$IMEXF video feature
Shorts lose again, keep it up !!
Based on #Bitcoin price current price of just over $8,000 US, @BlockOneCapital 2,000 #Bitcoinminers at full operability would generate revenue of approximately US$15,600,000 dollars. The chart below shows the potential revenue as it relates to the price of Bitcoin. $BLOK $BKPPF
https://twitter.com/EquityInsightCA/status/984876162953310208
Short Squeeze coming !! Watch out next week !!! LOL
Block One Capital's ICO Strategy Gives Investors Exposure To An Exclusive Asset Class
https://futuremoneytrader.com/crypto-market-news/block-one-capitals-ico-strategy-gives-investors-exposure-exclusive-asset-class
Holly !!!
2018-04-13 06:18 ET - News Release
Mr. Sothi Thillairajah reports
BLOCK ONE ANNOUNCES $2,000,000 NON-BROKERED PLACEMENT OFFERING PRICE APPROXIMATELY 40% ABOVE MARKET PRICE
Block One Capital Inc. has arranged a non-brokered placement of two million units at a price of $1 per unit for gross proceeds of $2-million. Each unit will consist of one common share in the capital of the company and one-half of one common share purchase warrant. Each full warrant shall be exercisable to acquire one additional share at a price of $1.50 for a period of two years from the date of closing. In the event that the shares trade at a closing price of greater than $2.50 per share for 10 consecutive trading days, the company may accelerate the expiry date of the warrants to expire on the 30th day after the date on which such notice is given by Block One.
The company intends to use the net proceeds of the offering to finance its continuing investment strategy in the cryptocurrency and blockchain space. The offering is expected to close immediately upon TSX Venture Exchange approval. All securities issued in connection with the offering will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.
https://www.stockwatch.com/News/Item.aspx?bid=Z-C:BLOK-2593366&symbol=BLOK®ion=C
GREAT READ $IMEXF, hints buyout by Boston Scientific
Medical Technology Advancements Spur New Opportunity For Investment
https://www.benzinga.com/pressreleases/18/04/b11504975/medical-technology-advancements-spur-new-opportunity-for-investment#/null
Hey Shorts !!
Word of advise..give it up and cover. You're going to get burned badly..
Tic Toc,,,
Ah you know what, forget that, keep trying, it will only make the squeeze that much stronger. See ya !
Each retailer invited their registered customers to create a Shopin profile, resulting in 719,000 sign-ups within 30 days. Based on personal shopper preferences and purchase data, Shopin was able to provide those registrants with curated recommendations, leading to a 22% lift in conversions, and yielding $14.7 million in additional sales. Of the shoppers who created a Shopin profile, 72,000 of them invited 65,000 additional new users to go through a Shopin onboarding.
Shopin will reach a massive market cap, Billion+ and that would make $BKPPF 750k investment 20x+
$BKKPF + SHOPIN
Own your data and get rewarded for it !!!
$IMEXF The Next Big Thing In Cancer Detection
https://financialstrend.com/the-next-big-thing-in-cancer-detection-45758.html
Block One Capital Inc. Initial Coin Offering (ICO) Investment Strategy & Addition Of Crypto Hedge Strategist
https://finance.yahoo.com/news/block-one-capital-inc-initial-070500274.html
VANCOUVER, B.C., March 27, 2018 (GLOBE NEWSWIRE) -- Block One Capital Inc. (BLOK.V) (BKPPF) (ES3.F) (the “Company” or “Block One”), an investment company focused on high growth opportunities in the blockchain and digital currency mining sector, is pleased to announce progress on it’s private token sale and pre-initial coin offering (ICO) investment strategy.
Over the past several months, Block One’s investment team has travelled the globe to meet numerous blockchain companies across various industry sectors and to evaluate both the business strategy and token use case scenarios of these token issuers.
Utilizing the benefits of Block One’s Investment Issuer and Institutional investor status, the company has identified a number of unique pre-ICO utility token allocation opportunities. As a result, Block One will be able to realize institutionally biased ticket size bonuses and gain access to private token sale offerings that typically will not come available for public sale to individuals. Often, access and exposure to quality, high impact token opportunities are too challenging and complex for individual investors to source and evaluate. Block One attempts to address this disadvantage that individual investors face, gaining premium quality exposure to the token issuance space.
“Upon reviewing numerous deals, I am excited about the pipeline of private token sale and pre-ICO investment opportunities we have identified. They are representative of what we feel are compelling opportunities led by proven entrepreneurs,” said Mr. Sothi Thillairajah, CEO. “I look forward to conveying the specific token allocations Block One will make in the coming weeks.”
Sudhu Arumugam Joins Block One Capital’s Advisory Board
Mr. Sudhu Arumugam is currently Head of Risk at Coinfloor UK Ltd, the UK’s oldest and largest crypto exchange. Tasked with building out a robust risk management infrastructure to support, on a 24/7 365 days basis, crypto trading across both multiple crypto currencies in both spot & derivatives contracts for Coinfloor’s UK entity as well as the global group of Companies.
Mr. Arumugam has over 20 years trading and risk management experience across fixed Income, equity, commodity and more recently crypto markets in both Europe and Asia.
Mr. Arumugam was Partner and Head of Trading at Cusaru Capital LLP. There he was managing portfolio hedging across rates, fixed income and commodities, which included Euribor and Sterling interest rate futures and options on LIFFE, 10 year fixed income US treasury futures and options on CME & European fixed income debt on Eurex.
At Sequoia Capital LLP, Mr. Arumugam was Partner, Head of Trading, Portfolio Hedging, Fixed Income and Interest Rate Trading on European government bond & interest rate options. In addition, he also helped Sequoia set up an office in Singapore, where he traded and subsequently risk managed (from London) Japanese nikkei index options & Japanese government bond options.
Prior to that, Mr. Arumugam was a Director of Equity Derivatives at Merrill Lynch International trading in the European technology, media and telecom sectors on a pan European basis in both listed, OTC & Exotic Options.
Mr. Arumugam began his career at the famed floor trading firm, Cooper Neff & Associates on the London International Financial Futures Exchange (LIFFE) and is a graduate of The City University, London.
For more information on Block One please visit the Company’s website at: www.blockonecap.com.
ON BEHALF OF THE BOARD
“Sothi Thillairajah”
Chief Executive Officer
Connect the dots this guy's a beast...
Update on Finzat : Michael W. Moore Named Chairman
https://globenewswire.com/news-release/2018/03/22/1444045/0/en/Block-One-Capital-Inc-Provides-Update-on-Finzat.html
Michael W. Moore Named Chairman
Finzat has named Michael W. Moore as the company’s Chairman. Mr. Moore is a recognized leader in mortgage finance and investment and risk management. During his 15 years as the senior-most financial executive with the Chicago Federal Home Loan Bank, he was the co-developer of Mortgage Partnership Finance (MPF), a mortgage origination platform whereby Federal Home Loan Bank (“FHLB”) members participate in a unique risk sharing arrangement with their respective FHLB, optimizing benefits for both parties. Mr. Moore in this new role as Executive Chairman is spearheading Finzat’s new product development in the housing market, which is a natural progression in validating Finzat’s token use case.
$BKPPF Blockchain Technology Creates Big Opportunity For Investors
http://coinchainmarket.com/article/blockchain-technology-creates-big-opportunity-investors/
GOLD NEWSLETTER ALERT #906
March 22, 2018
________________________________________
Gold Gets Fed
According to pattern, gold gets its usual post-Fed bump.
Is this the start of a new rally? Likely so, but nothing’s guaranteed these days.
Ho hum. Another Fed meeting, another gold bump in its wake.
That might be over-simplifying things somewhat, though. Gold’s propensity to weaken during the approach to an expected Fed rate hike and rally immediately thereafter has become so well known that the metal actually rose $8-$10 in the hours before the Fed announcement of a quarter-point hike yesterday and the release of its policy statement.
But that pre-positioning didn’t dampen investor enthusiasm for the metal post-announcement, as gold more than doubled those gains after the meeting and press conference.
By the end of yesterday’s session, spot gold had added $21.00, or 1.6%, to reach $1,331.80 bid. Silver offered encouraging leverage, adding $0.38 (2.35%) to $16.55, and the gold stock indices all surged around 3% or more.
With such a rousing rally in the metals sector after a rate hike, it’s not surprising that the market is taking a pause today. At last check, spot gold was off $6.60 (0.50%) at $1,325.20 bid, while silver was off $0.21 (1.24%) to $16.35. Platinum was trading $8.00 (0.84%) lower at $948, while palladium had fallen $4.00 (0.41%) to $982.
With the broader equity markets diving into the red (and the Dow down over 350 points) the gold stocks had no chance. The major indices are only off about 1%, though, so the damage hasn’t been too bad, and the two-day net is quite positive.
So the real question is whether this is a one-day wonder or the start of a bigger, longer rally.
And that question is impossible to answer. As I’ve been saying, the markets are responding in unpredictable fashion to the headlines. And with the headlines themselves being impossible to predict, anyone wishing to make short-term bets is simply playing a guessing game.
That said, gold is just below some important resistance levels around $1,330-$1,331, and some of our technical indicators had, before yesterday, delivered sell signals. So we’re in a crucial area, where a break through $1,331 over the next few days and through the end of the month could turn the charts solidly positive.
The opposite, of course, would be true if we don’t break through resistance.
Seems it’s always that way, doesn’t it?
So, as usual, we’ll track the daily moves, but keep our eye on the bigger picture — one that paints a long-term downtrend for the dollar and a corresponding uptrend for gold, as big investors switch their allegiance and money to currencies other than the greenback.
Drilling down, figuratively and a bit literally, I have a new recommendation for you...and it doesn’t have anything to do with gold.
In fact, it’s a play on lithium. You’re probably well aware that this sector has been hot in recent months and years, for all the battery-related reasons that we’ve all heard ad nauseam. Specific plays have also made headlines as they’ve been promoted high and low through major digital advertising programs.
But now that the sector has quieted a bit, I’m finding some interesting opportunities.
Specifically, I’ve had my eye on Far Resources (FAT.CN; FRRSF.OB; C$0.48) for a while. The company traded as high as double current levels when lithium plays were hotter.
At the time, I thought a little market-induced weakness would give us a good entry point, and indeed it has done so. Generally, the sector has cooled somewhat. But much more specifically, Far Resources has also been hit by the sudden illness and tragic passing, earlier this month, of highly regarded CEO Keith Anderson.
Keith first introduced me to this company a little over a year ago, and he was an exceedingly able and enthusiastic leader of the company. So much so that the stock took off before I could complete my due diligence and get a recommendation out.
I thought I’d missed the opportunity. But, again, the entire sector has settled back. And Far itself has encountered its own particular heartbreak with Keith’s passing.
The company is soldiering on in the face of the tragedy, with Interim CEO Toby Mayo at the helm. Far’s portfolio includes two promising lithium projects and a gold project that it is in the process of spinning out into a separate company.
Of its lithium projects, its Zoro project in Manitoba is the most advanced. A recently completed winter drilling program intersected wide intercepts of spodumene on a number of the dykes outlined on the project.
Along with the lithium brines of the “Lithium Triangle” in South America, lithium-spodumene bearing pegmatite is a key source of the lithium the world’s battery factories are currently gobbling up.
And while Australia is the largest producer of lithium from pegmatites, Canada has its share of lithium pegmatite projects, and Zoro is an excellent example of the type.
Far Resources has identified eight lithium-bearing pegmatites on Zoro to date. The recent work on Dyke 1 will help it bring that target’s significant historic resource into NI 43-101 compliance.
Prior work conducted on Zoro in the mid-1950s included 78 holes drilled and lithium grades as high as 1.4% over 49.8 meters. Intriguingly, the pegmatite mineralization appears to thicken at depth.
In addition to strong results from Dyke 1, the winter program at Zoro also encountered spodumene zones in Dykes 2, 4, 5 and 7.
It also encountered a new dyke of mineralization on a Mobile Metal Ions (MMI) geochemical anomaly. Holes from this target included Hole 34 and Hole 35, which graded up to 36.5 meters of spodumene-bearing pegmatite.
The assays from these and other holes will hit the market in the days and weeks ahead, providing a potential short-term catalyst for the share price that adds some urgency to this recommendation.
Longer-term, Far’s geologists will use the data from the recent work to build a three-dimensional model for grade and tonnage. Looking at the bigger picture, the grades at Zoro are quite good, and Far’s job will be to prove up a more-significant resource at those grades.
Given the recent drill results, the fact that surface samples have demonstrated exceptionally high grades and the on-going discovery of new dykes, I’ve concluded that the chances are excellent that the company will prove up a substantial hard-rock lithium resource at Zoro.
Management is excited about the momentum that strong assays from Zoro’s winter program may give the company. It is also enthused about the tantalum values it has encountered in soil sampling on the project.
With systematic field exploration of the project ongoing and the results of this latest drill program to be incorporated into a resource estimate, there are a number of potential news flow catalysts for Far Resources’ share price in the coming months.
Add in the longer-term potential of its Hidden Lake lithium project in Northwest Territories and the impending spin out of its gold asset in New Mexico, and you have a news-making lithium company with a gold kicker.
To participate in that kicker, though, you’ll need to own Far Resources prior to the spin out. The current lithium market appears to be cooperating by giving us a good entry point for Far prior to the coming flurry of news. It’s a buy.
— Brien Lundin
Most medical device companies grow by acquisition, not organically, Imagin Medical (IMEXF) has many liquidity options!!
Management Team
Done it before!!
Boston-based, experienced medical device management team that has done it before.
• Led by Jim Hutchens, founder of two medical device start-ups and executive at Boston Scientific and Smith & Nephew corporations
Patents
Exclusive license to three U.S. issued patents from Lawrence Livermore National Labs
• Collaborative Research Agreement gives Imagin right of first refusal for new IP
Summary
Imagin Medical is focused establishing a new standard of care in detecting cancer in minimally invasive surgeries where endoscopes are used.
• Initially targeting bladder cancer, plan to launch first product in 2Q19, expand to other minimally invasive surgeries (MIS)
• Patented, ultrasensitive imaging technology based on advanced optical design and light sensors
• Listed on the Canadian Securities Exchange (CSE) under the symbol “IME”, and the OTC Pink under the symbol “IMEXF”
$500M U.S. Market Segment
• Most expensive cancer to treat due to over 50% recurrence rate • 6th most prevalent cancer, 3rd most prevalent in men
• $4.0 billion spent annually on bladder cancer surveillance; 4M cystoscopies annually
• 75,000 new cases per year in U.S., 380,000 worldwide
The i/Blue Imaging System
• An advanced, ultrasensitive technology based on a combination of innovative optical design and light sensors. Expected to be 100x times more sensitive, dramatically improving the speed, quality and effectiveness of current systems. Works in conjunction with fluorescing imaging agents to deliver images far superior to conventional white light systems in far less time – 10 minutes vs. one hour
• Employs patented Simultaneous Acquisition of Differing Images that automatically blends white light and fluorescence images into one, putting the cancer in context within the bladder and freeing the surgeon from manually switching back and forth between different images to resect the cancer
Mitigated Development Risk:
Concept Proven, Working Prototype Completed, In-human Research Study Underway • Invented by Dr. Stavros Demos at Lawrence Livermore National Laboratory in California and concept validated at the University of California, Davis.
• Under Dr. Demos, final stage of development moved to Laboratory for Laser Energetics at the University of Rochester (UR). Collaborative Research Agreement in place and Dr. Demos continues to support Imagin’s development team.
• 10-patient research study currently underway (1Q18) at University of Rochester Medical Center to validate previous bench-testing results
Imagin Medical Overview
i/BLUE IMAGING SYSTEM™ BLADDER CANCER DETECTION
Today’s Standard of Care
• Endoscopes with White Light (Visible)
*90% of the market – today’s Gold Standard
*Highly effective if cancer protrudes above the bladder wall (See A below)
*Limitations – flat tumors often appear as normal tissue; difficult to see cancer cells along the margins (See B below)
• Endoscopes with White Light and Blue Filter with Fluorescing Contrast Agent
*Improves visibility of flat tumors and provides better view of the margins (See C below)
*Not practical due to the full hour it takes before the cancer becomes visible
* Requires the surgeon to switch back and forth between two separate images to resect the cancer o Blue image highlights the cancer but doesn’t show its precise location within the bladder
* White image that shows the full landscape of the bladder, but doesn’t highlight the cancer
Future Standard of Care - i/Blue Imaging System - Disruptive Technology
• “Sees” the cancer in less than 10 minutes vs. one hour; optics 100X more sensitive • Eliminates switching back and forth by automatically blending the “white” and “fluorescence” images into one, putting cancer in context and enabling the surgeon to better visualize and resect cancer
• Makes technology practical, not only for the O.R., but also for the physicians’ office, reducing healthcare costs
• Adaptable to other minimally invasive surgical procedures where endoscopes are used
Intellectual Property
Exclusive license to three U.S. issued patents from Lawrence Livermore National Labs • Collaborative Research Agreement gives Imagin right of first refusal for new IP
Management Team
Boston-based, experienced medical device management team that has done it before. • Led by Jim Hutchens, founder of two medical device start-ups and executive at Boston Scientific and Smith & Nephew corporations
Strong Acquisition Market
Most medical device companies grow by acquisition, not organically; company expects to have significant value and multiple liquidity options
$BKPPF Blockchain Technology Creates Big Opportunity For Investors
http://coinchainmarket.com/article/blockchain-technology-creates-big-opportunity-investors/
IME has a killer team, 3 members from BSX....a 38 Billion dollar company ! Who will most likely buy IME out shortly after Human Trial results
E. James Hutchens, Chief Executive Officer
Jim Hutchens is a proven entrepreneur with over 30 years of experience in general and marketing management in the medical technology industry. Mr. Hutchens served as a Managing Partner in Origin Partners, a $55 million early stage, venture capital fund and was the founder and CEO of both Microsurge Inc., a venture-backed, minimally invasive surgery company, and Choice Therapeutics, an advanced wound-care company which was sold to Alliqua Biomedical a NASDAQ list company. Mr. Hutchens also served in senior executive positions at Microvasive Endoscopy, a division of Boston Scientific, Smith & Nephew, and Millipore. He is a former member of the Board of Directors of the Brigham and Womens/ Faulkner Hospital and holds a BS in Business Administration from Boston University.
Michael G. Vergano, Director of Operations
Michael Vergano has been president of The Harvest Group Inc. since 1998, where he has provided consulting services for start-ups and major corporations in all phases of project management, including product development, packaging, quality systems, operations, manufacturing engineering, and system/process design and validation. During his more than 30 years in the medical device industry, Mr. Vergano also held management positions at Apple Medical, Inc. Ciba Corning Diagnostics, Microsurge, Inc. and Boston Scientific Corporation. He is the holder of 11 medical device patents. Mr. Vergano holds a Bachelor of Science in Mechanical Engineering from Tufts University.
Imagin Medical Inc. has hired Pam Papineau as the director of regulatory affairs.
Ms. Papineau has over 30 years of experience in quality and regulatory affairs with Baxter, Boston Scientific and Cogentix (Vision-Sciences), and has served as a consultant on a wide variety of devices that includes endoscopy, imaging, GI/GU, orthopedic and cardiovascular. Ms. Papineau has successfully prepared dozens of Food and Drug Administration premarket submissions and European Union (EU) technical files to support CE marking of a broad spectrum of medical devices and has overseen numerous clinical studies entailing protocol development, reporting and management of clinical research organization (CRO) services. Ms. Papineau is an ASQ Certified Quality Engineer (CQE), Certified Quality Auditor (CQA) and Certified Biomedical Auditor (CBA), an ISO 13485:2016 lead auditor, and holds Regulatory Affairs Professional Society (RAPS) certifications for the United States, EU and Canada. Ms. Papineau will work with Hogan Lovells, the company's legal counsel, preparing for a presubmission meeting with the FDA and follow-on activities through the regulatory approval process.
Good read while we wait for Human Trial results $IMEXF
Blue Light Cystoscopy Increases Bladder Cancer Detection Rate
http://usanewsgroup.com/2017/10/23/blue-light-cystoscopy-improves-detection-rate-2-2/
Data Shows the Growth in Value of Blockchain Markets
https://www.prnewswire.com/news-releases/data-shows-the-growth-in-value-of-blockchain-markets-676985293.html
Block One Capital Inc. (OTCQB: BKPPF) is an investment company focused on high growth opportunities in the blockchain and digital currency mining sector. Recently, the company announced that its investee company: TG12 Ventures Inc. ("TG12") has commenced mining Bitcoin. After a comprehensive review of the original site in Montreal selected for co-location, TG12 chose to co-locate the mining operation in Montana. The primary factors that led to the change were operational and cost efficiency - the contracted cost of power in Montana will be USD $0.031 per kwH.
Furthermore, the facility in Montana has four times more air circulation space allowing for cooler room temperatures, thereby improving the miner's overall efficiency and allowing for significant future scalability.TG12 was able to have the shipment of the miners rerouted to the Montana location ensuring that a setback in commencing mining of Bitcoin did not occur.
SHARING MY DD ON IME clinical trials.gov
How many investors here have actually gone to the Clinical Trials website where IME results are posted??
Here is the link
https://clinicaltrials.gov/ct2/show/NCT02967458?term=imaging+medical+inc&rank=1
I found it very interesting as they ALREADY STATE/REPORT.......the SHI new technology image machine that IME owns.......has clear evidence it WORKS! Says phase11 started Feb 21,2017 and it says 18months for results.
I also went way back to some ceo.ca posting, I copy/paste below. Indicates IME knows who will buy them out any thoughts on this post....who???
@CompoundIT Announcement on completed patient enrolment should come out soon...was told end of next week. All patients are from existing cases at Rochester. After that they start doing 1-2 patients per week. There will be news along the way concurrent to patients trial. In Feb all prelim patient data should be known. If all 10 cases produce results as claimed it better this company WILl get bought. Mgmt knows even who will be buying them if it comes to that. So if patient data confirms technology FDA approval will be 100% certain. 022 Nov 2017, 11:43
Clinicaltrials.gov..........Detailed Description:
Background: Prostate cancer (PCa) is the most frequently diagnosed cancer among American males, accounting for 27 % of new cancer diagnoses, but it is directly responsible for only 9.5 % of cancer related deaths. Two recently published clinical trials suggest that overdiagnosis and overtreatment of potentially insignificant cancer is a major drawback of prostate cancer screening, and point to the need for a more specific screening tool that can identify clinically significant prostate cancer. The US-based Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial failed to show a mortality benefit from screening and treatment of prostate cancer. The European Randomized Study of Screening for Prostate Cancer (ERSPC) suggests that with the current standard of care, 1410 men must be screened and 48 additional cases of prostate cancer treated to prevent one death from prostate cancer. Based upon these trials, the U.S. Preventive Services Task Force (USPSTF) has issued a grade "D" recommendation against PSA-based screening for PCa.
Contrast-Enhanced Ultrasound: Recent studies have demonstrated that contrast-enhanced harmonic imaging (HI) can identify enhancement related to vascular flow in higher grade PCa, and that HI can selectively detect patients with "clinically significant" PCa that are most likely to benefit from therapy. Subharmonic imaging (SHI) is a newer technology for contrast-enhanced ultrasound imaging that provides a 10-fold improvement in the signal to background ratio for visualization of small vascular structures, but has not been previously implemented on a transrectal ultrasound probe. SHI of the prostate is expected to advance the imaging of prostatic neovascularity and to improve selective biopsy of clinically significant PCa.
Objective: To adapt SHI to a transrectal probe appropriate for prostate imaging and biopsy (over the first 6 months of this study). The subsequent 18 month pilot clinical study will enroll 50 participants who have a clinical indication for prostate biopsy to quantify SHI for the detection of clinically significant PCa (defined as: Gleason score ≥ 7, a single core with > 50 % involvement, or > 25 % of biopsy cores positive for PCa).
Approach: Each participant will undergo a transrectal ultrasound evaluation of the prostate with conventional grayscale and color Doppler imaging, as well as contrast-enhanced imaging with color Doppler, HI and SHI approaches. Imaging results from each of these techniques will be recorded, but only the SHI findings will be used to guide a targeted biopsy of the prostate. A maximum of 6 targeted biopsy cores will be obtained from each participant, based upon suspicious areas identified with SHI. Following the targeted biopsy, each participant will also receive a 12-part systematic biopsy consisting of 6 laterally directed biopsy cores and 6 medially directed biopsy cores. The pilot study is designed to estimate the detection of clinically significant cancer that will be obtained with targeted biopsy based upon SHI along with the medially directed systematic sextant biopsy cores (≤ 12 cores total).
IMAGIN MEDICAL HIRES DIRECTOR OF REGULATORY AFFAIRS
Imagin Medical Inc. has hired Pam Papineau as the director of regulatory affairs.
Ms. Papineau has over 30 years of experience in quality and regulatory affairs with Baxter, Boston Scientific and Cogentix (Vision-Sciences), and has served as a consultant on a wide variety of devices that includes endoscopy, imaging, GI/GU, orthopedic and cardiovascular. Ms. Papineau has successfully prepared dozens of Food and Drug Administration premarket submissions and European Union (EU) technical files to support CE marking of a broad spectrum of medical devices and has overseen numerous clinical studies entailing protocol development, reporting and management of clinical research organization (CRO) services. Ms. Papineau is an ASQ Certified Quality Engineer (CQE), Certified Quality Auditor (CQA) and Certified Biomedical Auditor (CBA), an ISO 13485:2016 lead auditor, and holds Regulatory Affairs Professional Society (RAPS) certifications for the United States, EU and Canada. Ms. Papineau will work with Hogan Lovells, the company's legal counsel, preparing for a presubmission meeting with the FDA and follow-on activities through the regulatory approval process.
"As the project progresses, we continue to put the needed talent in place to bring the i/Blue Imaging System to market," said Jim Hutchens, Imagin's president and chief executive officer. "We have worked with Pam in the past and we're excited to have her expertise on our team."
About Imagin Medical Inc.
Imagin Medical is developing imaging solutions for the early detection of cancer where endoscopes are used. The company believes it will radically improve the way physicians detect cancer. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth-most prevalent in the United States, and the most costly cancer to treat due to a greater than 50-per-cent recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors.
1.50-$2 min
This is a game changer for cancer screening
Some of the most respected cancer Drs in North America are invovled
They should update on success in human trials this week.
this will work on many different cancers
every hospital and cancer dr in the world will use this going forward.
They hired a top FDA consultant for a reason. It works and fast track.
google the team behind this. They couldn't care less about the share price right now. It will be bought out within a year and brought to market.
Great news for crypto from G20 !! Get your bids ready $BKPPF
“The FSB’s initial assessment is that crypto-assets do not pose risks to global financial stability at this time,”
https://uk.reuters.com/article/us-g20-regulations-carney/g20-watchdog-focuses-on-rules-review-holds-fire-on-cryptocurrencies-idUKKBN1GU0SF
This is where you start buying IMEXF guys....a run is coming
The i/Blue system is expected to improve physicians’ ability to detect bladder cancer and reduce its recurrence by dramatically improving the urologist’s ability to visualize, identify and remove cancerous cells. The Company has completed development of its Alpha Prototype, an advanced optical and light sensor technology that, in conjunction with white light and near-infrared fluorescence, is expected to deliver superior images in less than 15 minutes vs. the full hour required by conventional systems. Imagin believes the time savings will increase the efficiency of the operating room and reduce healthcare costs by potentially enabling procedures to be performed in the less expensive physician’s office.
Take a look at these numbers:
https://twitter.com/CUUVETTE350
1000 rigs, Bitcoin $8000, Rev $829,500.00 / month, Profit $706,056.00 month
We know they have another 1000 rigs on the way for April
So at 8K Bitcoin, 2000 rigs , looking at:
$1.66 Million a month
$20 Million a year
This is all money that will be re-invested by the company
Now not ''if'' but when Bitcoin goes to 15k, 20k CASH COW
And they have Finzat, Mortgage Blockchain
Download full report from here:
https://futuremoneytrader.com/crypto-market-news/business-analysis-report-block-one-capital-inc
Block One Capital $BLOK $BKPPF is now generating revenue. Currently with 1,000 rigs,earning up to $830,000/month. Their new facility has up to 320 MW Capacity (enough for 160,000 rigs). The facility is operating at a low cost of electricity= 0.031per kwH
http://www.blockonecap.com/tg12-ventures-inc/
BKPPF is currently generating rev and profit, and it's not chump change
$830K a month at $8000 BTC with 1000 miners. Double that when they get the other batch of 1000 rigs.
Very true, but I'll take the 830K a month at $8000 BTC with 1000 miners any day. Double that when they get 2000 rigs. pic.twitter.com/Q5ZNsLxOhK
— CapitalGains (@CUUVETTE350) March 14, 2018